Nature Communications (Aug 2022)
A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy
- Brian D. Ross,
- Youngsoon Jang,
- Amanda Welton,
- Christopher A. Bonham,
- Dilrukshika S. W. Palagama,
- Kevin Heist,
- Jagadish Boppisetti,
- Kasun P. Imaduwage,
- Tanner Robison,
- Leah R. King,
- Edward Z. Zhang,
- Cyrus Amirfazli,
- Kathryn E. Luker,
- Winston Y. Lee,
- Gary D. Luker,
- Thomas L. Chenevert,
- Marcian E. Van Dort
Affiliations
- Brian D. Ross
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Youngsoon Jang
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Amanda Welton
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Christopher A. Bonham
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Dilrukshika S. W. Palagama
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Kevin Heist
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Jagadish Boppisetti
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Kasun P. Imaduwage
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Tanner Robison
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Leah R. King
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Edward Z. Zhang
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Cyrus Amirfazli
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Kathryn E. Luker
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Winston Y. Lee
- Department of Pathology, University of Michigan School of Medicine
- Gary D. Luker
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Thomas L. Chenevert
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- Marcian E. Van Dort
- Department of Radiology and the Center for Molecular Imaging, University of Michigan School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-32486-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
Combination therapies simultaneously inhibiting different therapeutic targets in cancer is challenged by individual pharmacokinetic profiles. Here, the authors generate an orally provided multi-targeted kinase inhibitor that is lymphatic absorbed and increases survival in a murine model of myelofibrosis.
